DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Bupropion for the Treatment of Methamphetamine Dependence - 1

Information source: National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Amphetamine-Related Disorders

Intervention: Bupropion (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: National Institute on Drug Abuse (NIDA)

Official(s) and/or principal investigator(s):
Richard Rawson, Ph.D., Principal Investigator, Affiliation: University of California, Los Angeles

Summary

The purpose of this study is to assess the efficacy and safety of bupropion in reducing methamphetamine use in subjects with methamphetamine dependence

Clinical Details

Official title: Bupropion for the Treatment of Methamphetamine Dependence

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Primary outcome:

Severity addiction

Methamphetamine use

Detailed description: A double-blind, placebo-controlled, parallel-group design study in which 100 subjects will be randomly assigned to placebo or bupropion for 12 weeks with follow-up assessments 4 weeks following treatment. Adaptive randomization will be used to balance treatment groups based on gender.

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Subject must have methamphetamine dependence as determined by the DSM-IV diagnosis

- Subject must be willing to comply with study procedures.

- Ability to verbalize understanding of consent form, provide written consent, and

verbalize willingness to complete study procedures

- Be able to comply with protocol requirements

Exclusion Criteria:

- Please contact site for more information.

Locations and Contacts

Matrix Institute on Addictions, Costa Mesa, California 92627, United States

South Bay Treatment Center, San Diego, California 92105, United States

Pacific Addiction Research Center, Honolulu, Hawaii 96813, United States

Powell Chemical Dependency Center, Des Moines, Iowa 50316, United States

University of Missouri - Kansas City, Kansas City, Missouri 64108, United States

Additional Information

Starting date: July 2003
Last updated: July 21, 2008

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017